News

Company   ImmuPharma PLC
TIDM         IMM
Headline     Best Drug Development Company in Europe Award
Released    09:26 08-Apr-2010
Number     8786J09

FOR IMMEDIATE RELEASE

London, 8 April 2010

ImmuPharma awarded Best Drug Development Company in Europe Award

ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company, has been voted "Best Drug Development Company, Europe" at The New Economy Pharmaceutical & Healthcare Awards 2010.

This award follows on from two notable wins in 2009 namely; "Best Technology Award" at the AIM Awards, organized by the London Stock Exchange and "Breakthrough of the year 2009" at the European Mediscience Awards.

For further information please contact:

ImmuPharma PLC +44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer
Richard Warr, Chairman

Buchanan Communications +44 20 7466 5000

Lisa Baderoon
George Prassas

Panmure Gordon & Co (NOMAD and Broker) +44 151 243 0963

Andrew Burnett
Rakesh Sharma

Noble & Company Limited (Joint Broker) +44 20 7763 2200

James Bromhead

Notes to Editors

About ImmuPharma PLC

ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders.

Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date.

The company also has a strong proprietary and collaborative drug development pipeline.


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Best Drug Development Company in Europe Award Released 09:26 08-Apr-2010 Number 8786J09 FOR IMMEDIATE RELEASE London, 8 April 2010 ImmuPharma awarded Best Drug Development Company in Europe Award ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company, has been voted "Best Drug Development Company, Europe" at The New Economy Pharmaceutical & Healthcare Awards 2010. This award follows on from two notable wins in 2009 namely; "Best Technology Award" at the AIM Awards, organized by the London Stock Exchange and "Breakthrough of the year 2009" at the European Mediscience Awards. For further information please contact: ImmuPharma PLC +44 20 7152 4080 Dimitri Dimitriou, Chief Executive Officer Richard Warr, Chairman Buchanan Communications +44 20 7466 5000 Lisa Baderoon George Prassas Panmure Gordon & Co (NOMAD and Broker) +44 151 243 0963 Andrew Burnett Rakesh Sharma Noble & Company Limited (Joint Broker) +44 20 7763 2200 James Bromhead Notes to Editors About ImmuPharma PLC ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders. Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date. The company also has a strong proprietary and collaborative drug development pipeline. ©2010 London Stock Exchange plc. All rights reserved